| 货号 | 13648-5mg |
| 描述 | Alfuzosin is a post-synaptic α1-adrenergic receptor antagonist commonly used to improve lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).1,2 It displays high-affinity with non-selectivity for the three known human α1 adrenoceptors (pKi = 8.0, 8.0, and 8.5 for α1A, α1B, and α1D, respectively).3 Consistent with a role for α1 adrenoceptors in mediating contraction of smooth muscle, alfuzosin was first described as having anti-hypertensive effects with peripheral vasodilator properties.1 In patients with BPH, alfuzosin increases mean urinary flow rate and decreases residual volume.2 Alfuzosin produces minimal vasodilatory and sexual function side effects.4,5,6 |
| 别名 | SL 77499-10;Uroxatral; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Sinclair, A.J.,Davies, I.B., and Warrington, S.J. Alfuzosin and the venous reflex response: Studies in normal subjects. British Journal of Clinical Pharmacology 27, 19-22 (1989). 2.Jardin, A.,Bensadoun, H.,Delauche-Cavallier, M.C., et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337, 1457-1461 (1991). 3.Kenny, B.A.,Miller, A.M.,Williamson, I.J.R., et al. Evaluation of the pharmacological selectivity profile of α1 adrenoceptor antagonists at prostatic α1 adrenoceptors: Binding, functional and in vivo studies. British Journal of Pharmacology 118, 871-878 (1996). 4.Roehrborn, C.G., and Rosen, R.C. Medical therapy options for aging men with benign prostatic hyperplasia: Focus on alfuzosin 10 mg once daily. Clinical Interventions in Aging 3(3), 511-524 (2008). 5.Nickel, J.C.,Sander, S., and Moon, T.D. A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia. International Journal of Clinical Practice 62(10), 1547-1559 (2008). 6.Michel, M.C. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: α-blockers in the treatment of male voiding dysfunction - how do they work and why do they differ in tolerability? Journal of Pharmacological Sciences 112, 151-157 (2010). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 425.9 |
| 分子式 | C19H27N5O4 • HCl |
| CAS号 | 81403-68-1 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |